PDGFRA and Increased total eosinophil count: These neoplasms, such as chronic eosinophilic leukemia with FIP1L1-PDGFRA fusion, are characterized by clonal eosinophilia and often respond well to tyrosine kinase inhibitors like imatinib (36).